Utidelone plus Metronomic Capecitabine — Competitive Intelligence Brief

Utidelone plus Metronomic Capecitabine (Utidelone plus Metronomic Capecitabine) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Chemotherapy. Area: Oncology.

phase 3 Chemotherapy Topoisomerase II, Thymidylate synthase Oncology Small molecule

Target snapshot

Utidelone plus Metronomic Capecitabine (Utidelone plus Metronomic Capecitabine) — Sun Yat-sen University. Utidelone is a chemotherapy medication that works by interfering with DNA replication, while metronomic capecitabine is a prodrug that is converted into 5-fluorouracil, which inhibits thymidylate synthase.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Utidelone plus Metronomic Capecitabine TARGET	Utidelone plus Metronomic Capecitabine	Sun Yat-sen University	phase 3	Chemotherapy	Topoisomerase II, Thymidylate synthase
Eloxatin	Oxaliplatin	Yakult Honsha	marketed	Platinum-based chemotherapy agent	DNA	2002-01-01
Consolidation Chemotherapy	Consolidation Chemotherapy	National Cancer Center Affiliate of Vilnius University Hospital Santaros Klinikos	marketed	Combination chemotherapy regimen
ATRA+Chemo	ATRA+Chemo	Shanghai Jiao Tong University School of Medicine	marketed	Retinoid + chemotherapy combination	Retinoic acid receptor (RAR)
aflibercept + FOLFIRI	aflibercept + FOLFIRI	CR-CSSS Champlain-Charles-Le Moyne	marketed	VEGF inhibitor (fusion protein) + chemotherapy combination	VEGF-A, VEGF-B, PlGF (aflibercept component); topoisomerase I and thymidylate synthase (FOLFIRI component)
Adjuvant chemotherapy	Adjuvant chemotherapy	Institut de Cancérologie de Lorraine	marketed	Chemotherapy regimen (multi-agent or single-agent cytotoxic)
Carboplatin or Cisplatin	Carboplatin or Cisplatin	Second Hospital of Shanxi Medical University	marketed	Platinum-based chemotherapy agent	DNA

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Chemotherapy class)

1. University Hospital, Rouen · 2 drugs in this class
2. Sun Yat-sen University · 2 drugs in this class
3. Assistance Publique - Hôpitaux de Paris · 2 drugs in this class
4. Beijing Biostar Pharmaceuticals Co., Ltd. · 1 drug in this class
5. Delcath Systems Inc. · 1 drug in this class
6. Ludwig-Maximilians - University of Munich · 1 drug in this class
7. Prof. Dr. med. Claus Rödel · 1 drug in this class
8. Prothena Biosciences Ltd. · 1 drug in this class
9. Seoul National University Hospital · 1 drug in this class
10. Shanghai Zhongshan Hospital · 1 drug in this class